Skip to main content
SpringerLink
Log in
Book cover

T1-Mapping in Myocardial Disease pp 87–100Cite as

T1 Mapping in Stem Cell Therapy

  • Chapter
  • First Online:

  • 310 Accesses

Abstract

Cell therapy is increasingly seen as a viable technique to recover myocardial function by reverse remodeling. The goal of cell therapy is the functional recovery of the heart and consequently prognostic improvement, but the results of prior research has been inconsistent and controversial. Basic science experiments have also shown that cell therapy may improve myocardial function by reducing myocardial fibrosis and promoting the growth of active myocytes. From the aspect of imaging, late gadolinium enhancement imaging alone may not be sufficient to identify the effects of cell therapy. T1 mapping with its’ increased sensitivity to detect diffuse interstitial fibrosis may be seen as a viable and attractive endpoint, particularly, as it pertains to subtle changes in the structure of the underlying extracellular matrix. T1 mapping has also shown prognostic value in studies in participants with non-ischemic cardiomyopathy. The rationale to use T1 mapping in stem cell therapy exists on its utility to assess current disease status, as well as the assessment of future prognosis.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Chiu RC, Zibaitis A, Kao RL. Cellular cardiomyoplasty: myocardial regeneration with satellite cell implantation. Ann Thorac Surg. 1995;60:12–8.

    Article  CAS  PubMed  Google Scholar 

  2. Perin EC, Dohmann HFR, Borojevic R, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003;107(18):2294–302. https://doi.org/10.1161/01.CIR.0000070596.30552.8B.

    Article  PubMed  Google Scholar 

  3. Psaltis PJ, Zannettino ACW, Gronthos S, Worthley SG. Intramyocardial navigation and mapping for stem cell delivery. J Cardiovasc Transl Res. 2010;3:135–46.

    Article  PubMed  Google Scholar 

  4. Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364:141–8.

    Article  PubMed  Google Scholar 

  5. Lunde K, Solheim S, Aakhus S, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006;355:1199–209.

    Article  CAS  PubMed  Google Scholar 

  6. Hirsch A, Nijveldt R, van der Vleuten PA, et al. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE. Eur Heart J. 2011;32:1736–47.

    Article  PubMed  Google Scholar 

  7. Malliaras K, Makkar RR, Smith RR, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol. 2014;63:110–22.

    Article  PubMed  Google Scholar 

  8. Bolli R, Chugh AR, D’Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet (London, England). 2011;378:1847–57.

    Article  Google Scholar 

  9. Heldman AW, DiFede DL, Fishman JE, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014;311:62–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Fischer-Rasokat U, Assmus B, Seeger FH, et al. A pilot trial to assess potential effects of selective intracoronary bone marrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and functional regenerat. Circ Heart Fail. 2009;2:417–23.

    Article  CAS  PubMed  Google Scholar 

  11. Seth S, Bhargava B, Narang R, Ray R, Mohanty S, Gulati G, Kumar L, Airan B, Venugopal P, AIIMS Stem Cell Study Group. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial a long-term follow-up study. J Am Coll Cardiol. 2010;55:1643–4.

    Article  PubMed  Google Scholar 

  12. Vrtovec B, Poglajen G, Lezaic L, Sever M, Socan A, Domanovic D, Cernelc P, Torre-Amione G, Haddad F, Wu JC. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation. 2013;128:S42–9.

    Article  CAS  PubMed  Google Scholar 

  13. Hare JM, DiFede DL, Rieger AC, et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2017;69:526–37.

    Article  PubMed  Google Scholar 

  14. Lee J-W, Lee S-H, Youn Y-J, et al. A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction. J Korean Med Sci. 2014;29:23.

    Article  PubMed  Google Scholar 

  15. Madonna R, Van Laake LW, Davidson SM, et al. Position paper of the European Society of Cardiology Working Group cellular biology of the heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. Eur Heart J. 2016;37:1789–98.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy. JAMA. 2012;308:2369.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Charoenpanichkit C, Hundley W. The 20 year evolution of dobutamine stress cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12:59.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months’ follow-up data from the randomized, controlled BOOST (Bone marrow transfer to enhance ST-elevation infarct regeneration) trial. Circulation. 2006;113:1287–94.

    Article  PubMed  Google Scholar 

  19. Fisher SA, Zhang H, Doree C, Mathur A, Martin-Rendon E. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev. 2015;(2):CD006536.

    Google Scholar 

  20. Afzal MR, Samanta A, Shah ZI, Jeevanantham V, Abdel-Latif A, Zuba-Surma EK, Dawn B. Adult bone marrow cell therapy for ischemic heart disease: evidence and insights from randomized controlled trials. Circ Res. 2015;117:558–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Henry TD, Moyé L, Traverse JH. Consistently inconsistent-bone marrow mononuclear stem cell therapy following acute myocardial infarction: a decade later. Circ Res. 2016;119:404–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Suerder D, Manka R, Moccetti T, et al. The effect of bone marrow derived mononuclear cell treatment, early or late after acute myocardial infarction: twelve months CMR and long-term clinical results. Circ Res. 2016;119(3):481–90. https://doi.org/10.1161/CIRCRESAHA.116.308639.

    Article  CAS  Google Scholar 

  23. Solomon SD, Anavekar N, Skali H, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005;112:3738–44.

    Article  PubMed  Google Scholar 

  24. Hsu JJ, Ziaeian B, Fonarow GC. Heart failure with mid-range (borderline) ejection fraction. JACC Hear Fail. 2017;5:763–71.

    Article  Google Scholar 

  25. Yan AT, Shayne AJ, Brown KA, Gupta SN, Chan CW, Luu TM, Di Carli MF, Reynolds HG, Stevenson WG, Kwong RY. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation. 2006;114:32–9.

    Article  PubMed  Google Scholar 

  26. Avelar E, Strickland CR, Rosito G. Role of imaging in cardio-oncology. Curr Treat Options Cardiovasc Med. 2017;19(6):46. https://doi.org/10.1007/s11936-017-0546-2.

    Article  PubMed  Google Scholar 

  27. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445–53.

    Article  CAS  PubMed  Google Scholar 

  28. Hamirani YS, Wong A, Kramer CM, Salerno M. Effect of microvascular obstruction and intramyocardial hemorrhage by CMR on LV remodeling and outcomes after myocardial infarction: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2014;7:940–52.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Gulati A, Jabbour A, Ismail TF, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309:896–908.

    Article  CAS  PubMed  Google Scholar 

  30. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, Sheppard MN, Poole-Wilson PA, Pennell DJ. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1977–85.

    Article  PubMed  Google Scholar 

  31. Bruder O, Wagner A, Jensen CJ, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:875–87.

    Article  PubMed  Google Scholar 

  32. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501–11.

    Article  PubMed  Google Scholar 

  33. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J. 2005;26:1461–74.

    Article  PubMed  Google Scholar 

  34. Puntmann VO, Carr-White G, Jabbour A, et al. T1-mapping and outcome in nonischemic cardiomyopathy. JACC Cardiovasc Imaging. 2016;9:40–50.

    Article  PubMed  Google Scholar 

  35. Neilan TG, Coelho-Filho OR, Shah RV, et al. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am J Cardiol. 2013;111:717–22.

    Article  CAS  PubMed  Google Scholar 

  36. Ambale-Venkatesh B, Lima JAC. Cardiac MRI: a central prognostic tool in myocardial fibrosis. Nat Rev Cardiol. 2015;12:18–29.

    Article  CAS  PubMed  Google Scholar 

  37. Mewton N, Liu CY, Croisille P, Bluemke D, Lima JAC. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57:891–903.

    Article  PubMed  Google Scholar 

  38. Maestrini V, Treibel TA, White SK, Fontana M, Moon JC. T1 mapping for characterization of intracellular and extracellular myocardial diseases in heart failure. Curr Cardiovasc Imaging Rep. 2014;7:1–7.

    Article  Google Scholar 

  39. Puntmann VO, Peker E, Chandrashekhar Y, Nagel E. T1 mapping in characterizing myocardial disease: a comprehensive review. Circ Res. 2016;119:277–99.

    Article  CAS  PubMed  Google Scholar 

  40. Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson. 2017;18:89.

    Article  Google Scholar 

  41. Liu C-Y, Liu Y-C, Wu C, et al. Evaluation of age-related interstitial myocardial fibrosis with cardiac magnetic resonance contrast-enhanced T1 mapping: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2013;62:1280–7.

    Article  PubMed  Google Scholar 

  42. Donekal S, Venkatesh BA, Liu YC, et al. Interstitial fibrosis, left ventricular remodeling, and myocardial mechanical behavior in a population-based multiethnic cohort: the multi-ethnic study of atherosclerosis (mesa) study. Circ Cardiovasc Imaging. 2014;7:292–302.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Inoue YY, Ambale-Venkatesh B, Mewton N, et al. Electrocardiographic impact of myocardial diffuse fibrosis and scar: MESA (Multi-Ethnic Study of Atherosclerosis). Radiology. 2017;282:690–8.

    Article  PubMed  Google Scholar 

  44. Yi CJ, Wu CO, Tee M, et al. The association between cardiovascular risk and cardiovascular magnetic resonance measures of fibrosis: the Multi-Ethnic Study of Atherosclerosis (MESA). J Cardiovasc Magn Reson. 2015;17(1):15.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Reinstadler SJ, Stiermaier T, Liebetrau J, et al. 9Prognostic significance of remote myocardium alterations assessed by quantitative noncontrast T1 mapping in ST-segment elevation myocardial infarction. JACC Cardiovasc Imaging. 2017;11(3):411–9. https://doi.org/10.1016/j.jcmg.2017.03.015.

    Article  PubMed  Google Scholar 

  46. Biesbroek PS, Amier RP, Teunissen PFA, Hofman MBM, Robbers LFHJ, van de Ven PM, Beek AM, van Rossum AC, van Royen N, Nijveldt R. Changes in remote myocardial tissue after acute myocardial infarction and its relation to cardiac remodeling: a CMR T1 mapping study. PLoS One. 2017;12:1–13.

    Article  CAS  Google Scholar 

  47. Youn J-C, Hong YJ, Lee H-J, et al. Contrast-enhanced T1 mapping-based extracellular volume fraction independently predicts clinical outcome in patients with non-ischemic dilated cardiomyopathy: a prospective cohort study. Eur Radiol. 2017;27(9):3924–33. https://doi.org/10.1007/s00330-017-4817-9.

    Article  PubMed  Google Scholar 

  48. Hamdy A, Kitagawa K, Ishida M, Sakuma H. Native myocardial T1 mapping, are we there yet? Int Heart J. 2016;57:400–7.

    Article  PubMed  Google Scholar 

  49. Venkatesh BA, Volpe GJ, Donekal S, et al. Association of longitudinal changes in left ventricular structure and function with myocardial fibrosis: the Multi-Ethnic Study of Atherosclerosis study. Hypertension. 2014;64:508–15.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Yoko Kato, Mohammad R. Ostovaneh & Joao Lima

  2. Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Bharath Ambale-Venkatesh & Joao Lima

Authors
  1. Yoko Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammad R. Ostovaneh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bharath Ambale-Venkatesh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joao Lima
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bharath Ambale-Venkatesh .

Editor information

Editors and Affiliations

  1. School of Medicine, Stanford University School of Medicine, Stanford, CA, USA

    Phillip C. Yang

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kato, Y., Ostovaneh, M.R., Ambale-Venkatesh, B., Lima, J. (2018). T1 Mapping in Stem Cell Therapy. In: Yang, P. (eds) T1-Mapping in Myocardial Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-91110-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-91110-6_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-91109-0

  • Online ISBN: 978-3-319-91110-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation